Siguazodan

CAS : 115344-47-3

Ref. 3D-QEA34447

Informations sur le produit

• Nom: Siguazodan
• Synonymes: 1-Cyano-2-Methyl-3-[4-(4-Methyl-6-Oxo-1,4,5,6-Tetrahydropyridazin-3-Yl)Phenyl]Guanidine, Guanidine, N-cyano-N′-methyl-N′′-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-, N-Cyano-N'-Methyl-N'-[4-(1,4,5,6-Tetrahydro-4-Methyl-6-Oxo-3-Pyridazinyl)Phenyl]Guanidine, N-Cyano-Nmethyl-N��-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]guanidine, Siguazodan (SKF 94836), Siguazodan, N-Cyano-Nμ-methyl-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]guanidine, Sk And F-94836, Skf 94836

Description

Siguazodan is a phosphodiesterase inhibitor that is used for the treatment of congestive heart failure and bowel disease. Siguazodan inhibits the activity of cyclic nucleotide phosphodiesterases, which are enzymes that regulate the concentration of cyclic AMP (cAMP) in cells. It has anti-inflammatory properties and can be used to inhibit the bronchoconstrictor response. Siguazodan also inhibits phosphodiesterase-4 (PDE4), an enzyme that degrades cAMP, increasing intracellular concentrations and causing bronchodilation.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 284.32 g/mol
• Formule: C₁₄H₁₆N₆O
• Degré de pureté: Min. 95%